Pay in 4 interest-free payments of $7.12 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Pfizer moves forward a daily GLP-1 obesity pill Pfizer will advance a once-daily formulation of its oral GLP-1 obesity candidate, danuglipron, after facing multiple setbacks in the space
Table 1 Key mechanistic pathways linking the oral-gut axis to systemic health
Retatrutide sIde effects like nausea, diarrhea, and constipation are more common at higher doses and tend to occur mainly during the dose-escalation period
Companies matching tech setups with changing formulation requirements will be at the forefront of determining the best practice for contract manufacturing weight-loss therapeutics
A meta-analysis of initial research showed that GLP-1s reduced the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes (T2D) by 14%, all-cause mortality by 12%, hospital admissions for heart failure by 11%, and the composite kidney outcome by 21%
Anything that increases inflammation: There are more obvious things that increase inflammation like lack of sleep, a diet high in inflammatory foods, smoking, or underlying infections
US$ 25.33
US$ 27.81
US$ 21.60
